Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, reported Q2 2025 financial results and corporate updates. The company initiated TibuSHIELD, a Phase 2 study of tibulizumab for hidradenitis suppurativa, and continued progress on TibuSURE, another Phase 2 study for systemic sclerosis, with data readouts expected in Q3 2026 and Q4 2026 respectively.
Financial highlights include $154.5 million in cash and equivalents as of June 30, 2025, expected to fund operations through 2027. Q2 2025 net loss was $16.0 million ($0.17 per share), compared to $10.3 million in Q2 2024. R&D expenses increased to $8.7 million from $5.5 million year-over-year, while G&A expenses rose to $9.4 million from $6.2 million.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has granted inducement stock options to seven new employees. The company awarded options to purchase up to 890,950 Class A Ordinary Shares, including 672,000 options to newly appointed CFO Eric Hyllengren.
The grants, approved by the Compensation Committee and Board on July 15, 2025, were made outside the company's 2023 Equity Incentive Plan as employment inducements under Nasdaq Rule 5635(c)(4). The options vest 25% initially, followed by quarterly installments of 1/12th of remaining shares, subject to continued employment.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren will succeed Verender Badial, who will remain with the company as a non-executive employee through July 31, 2025, to ensure a smooth transition.
Hyllengren brings over 20 years of financial leadership experience in life sciences and biotechnology. He previously served as COO and CFO at Atara Biotherapeutics, where he managed strategic finance, capital markets, operational planning, and other key functions. Before that, he spent 15 years at Amgen in various roles including corporate finance, investor relations, and business development.
Badial, who joined Zura Bio in March 2023 during its business combination with JATT Acquisition Corporation, helped develop the company's financial systems and participated in capital-raising initiatives during his tenure.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's senior leadership will deliver a corporate overview on June 4, 2025, at 3:10 PM ET in New York. The presentation will be accessible via live webcast on Zura Bio's website, with a replay available for at least 30 days afterward. Additionally, the company will engage in one-on-one meetings with investors during the conference.
Zura Bio (NASDAQ: ZURA) reported its full year 2024 financial results, highlighting significant operational and financial achievements. The company completed a $112.5 million private placement in April 2024, ending the year with $176.5 million in cash and cash equivalents, providing runway through 2027.
Key developments include initiating the Phase 2 TibuSURE trial for systemic sclerosis and plans to launch a Phase 2 study for hidradenitis suppurativa in Q2 2025. Financial results show R&D expenses decreased to $24.4 million from $44.0 million in 2023, while G&A expenses increased to $30.8 million from $18.6 million. The company reported a net loss of $45.4 million ($0.60 per share) compared to $69.2 million ($2.09 per share) in 2023.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, March 11, 2025, at 1:40 p.m. ET in Miami, FL, where they will also host investor meetings.
The presentation will be accessible through a live webcast on the News & Events page of Zura Bio's website's Investors & Media section. For those unable to attend, a replay will be available and archived on the website for a minimum of 30 days after the event.
Zura Bio (NASDAQ: ZURA) has launched TibuSURE, a global Phase 2 study evaluating tibulizumab for treating systemic sclerosis (SSc) in adults. The study marks the first clinical trial designed to investigate both anti-BAFF and IL-17 pathways in systemic sclerosis. Tibulizumab's dual-pathway approach aims to provide deeper efficacy compared to single-pathway inhibition, which has shown modest effects in rheumatic diseases like SSc.
The company believes this novel strategy of concurrently targeting two pivotal pathways involved in inflammation and fibrosis could address the multi-organ pathology of SSc, a heterogeneous and complex autoimmune disease with effective therapies currently available.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focusing on dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, December 3, 2024, at 9:00 a.m. ET in New York, NY, and will conduct investor meetings. A live webcast and replay of the presentation will be accessible on the company's website's Investors section under 'News & Events,' remaining available for at least 30 days after the event.